Helius Medical Technologies, Inc.
Stock Promoter Performance
Last 3 Stock Promotions By "Stock Palooza"
|Symbol||Company||Start Date||Trades||Money Flow||Open||Close||Change|
|OMVS||On The Move Systems Corp.||August 4, 2015||1,043||$259,577||3.65||2.90||-11%|
|SNGX||Soligenix, Inc.||June 25, 2015||887||($38,281)||2.62||2.40||-4%|
|TPIV||TapImmune, Inc.||June 24, 2015||1,717||($687,345)||1.53||1.47||-3%|
HSDT Promotional Newsletter
The following is a newsletter released by "Stock Palooza" promoting Helius Medical Technologies, Inc.
Here come another Bio Tech Play HSDT.PK
HSDT have been stabilizing right about .75 cents All time Low
HSDT is definitely over sold which mean opportunity for our traders
Please see HSDT's last Press Release
U.S. Army and Helius Medical Technologies Announce Launch of Phase 3 Traumatic Brain Injury Clinical Trial
NEWTOWN, Pa.--BUSINESS WIRE--
Helius Medical Technologies CSEHSM Helius, or the Company and the U.S. Army Medical Research and Materiel Command USAMRMC announce the launch of a Phase 3 clinical trial to investigate the safety and effectiveness of the Portable Neuromodulation Stimulator PoNS 4.0 device, a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury mTBI. The trial is intended to serve as the basis for seeking Canadian and U.S. marketing approvals of the PoNS. The PoNS is an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue.
The trial, a double-blind, randomized, sham-controlled study of the safety and effectiveness of the PoNS device for cranial nerve noninvasive neuromodulation CN-NINM training in subjects with a chronic balance deficit due to mTBI, is a seven-month study being conducted at three sites the Montreal Neurofeedback Center the Oregon Health Science University Center for Regenerative Medicine and the Orlando Regional Medical Center. A total of 120 subjects will participate in the study. The primary endpoint at five weeks is improvement in chronic balance deficit as analyzed by the Sensory Organization Test SOT. The purpose of this study is to demonstrate that cranial nerve non invasive neuromodulation CN-NINM, which combines the PoNS device with a unique physiotherapy regiment, may provide new rehabilitative opportunities for patients suffering from chronic symptoms.
Together with our partners at the USAMRMC, we are very pleased to announce the launch of our pivotal Phase 3 mTBI trial today, said Helius CEO, Philippe Deschamps. Traumatic Brain Injury TBI remains a serious public health problem both for the military and civilian populations for which there have been almost no new developments in treatment since the introduction of physical therapy several decades ago. There is also a large population of TBI patients who develop chronic symptoms, for which traditional physical therapy has proven ineffective.
We are excited to begin the clinical trials for the PoNS device as a potential treatment for symptoms of TBI in our Wounded Warriors, said Dr. Kenneth Bertram, Principal Assistant for Acquisition, USAMRMC. We are committed to the laboratory and clinical research needed to improve the treatment of brain injury.
The first site to begin recruitment and screening will be the Montreal Neurofeedback Center.
TBI has always been an issue of high unmet need in Canada and in the United States, and we are proud and excited for the opportunity to lead the clinical development of this breakthrough technology, said Dr. Alain Ptito, Neuropsychologist and Principal Investigator of the study.
To learn more about the study, please visit
I'll talk to you soon
11020 Vanowen St No. Hollywood CA 91605
Get Every Penny Stock Alert!
OTC Dynamics tracks all penny stock promotions. Become a member today and never miss another penny stock promotion!
OTC Dynamics is not affiliated with the company being promoted or the associated stock promoter.
The information on this page is not a recommendation to buy or sell securities.